JP2023540259A5 - - Google Patents

Info

Publication number
JP2023540259A5
JP2023540259A5 JP2023513877A JP2023513877A JP2023540259A5 JP 2023540259 A5 JP2023540259 A5 JP 2023540259A5 JP 2023513877 A JP2023513877 A JP 2023513877A JP 2023513877 A JP2023513877 A JP 2023513877A JP 2023540259 A5 JP2023540259 A5 JP 2023540259A5
Authority
JP
Japan
Prior art keywords
groups
alkyl
substituted
pharmaceutical composition
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513877A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540259A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2021/050978 external-priority patent/WO2022040741A1/en
Publication of JP2023540259A publication Critical patent/JP2023540259A/ja
Publication of JP2023540259A5 publication Critical patent/JP2023540259A5/ja
Pending legal-status Critical Current

Links

JP2023513877A 2020-08-26 2021-08-25 肺感染症の治療および予防用のグルコシダーゼ阻害剤 Pending JP2023540259A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020903051 2020-08-26
AU2020903051A AU2020903051A0 (en) 2020-08-26 Compounds, compositions and uses thereof
PCT/AU2021/050978 WO2022040741A1 (en) 2020-08-26 2021-08-25 Glucosidase inhibitors for the treatment and prevention of pulmonary infections

Publications (2)

Publication Number Publication Date
JP2023540259A JP2023540259A (ja) 2023-09-22
JP2023540259A5 true JP2023540259A5 (cg-RX-API-DMAC7.html) 2024-08-14

Family

ID=80352192

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513877A Pending JP2023540259A (ja) 2020-08-26 2021-08-25 肺感染症の治療および予防用のグルコシダーゼ阻害剤

Country Status (6)

Country Link
US (1) US20240016786A1 (cg-RX-API-DMAC7.html)
EP (1) EP4203954A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023540259A (cg-RX-API-DMAC7.html)
CN (1) CN116419754A (cg-RX-API-DMAC7.html)
AU (1) AU2021332085B2 (cg-RX-API-DMAC7.html)
WO (1) WO2022040741A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100027464A1 (it) * 2021-10-26 2023-04-26 Univ Degli Studi Di Camerino Composizione comprendente iminozuccheri e/o anisodamina per il trattamento di infezioni virali
US12569473B2 (en) * 2022-07-05 2026-03-10 60 Degrees Pharmaceuticals, Inc. Methods to treat respiratory infection utilizing castanospermine analogs
CN119841765B (zh) * 2025-01-09 2025-10-10 中南大学 Dnj衍生物、药物组合物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1876095A (en) * 1994-02-25 1995-09-11 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
GB0116643D0 (en) * 2001-07-09 2001-08-29 Virogen Ltd Antiviral compounds
FR2861991B1 (fr) * 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
WO2011095772A2 (en) * 2010-02-04 2011-08-11 Summit Corporation Plc Novel iminosugar therapeutics
RS58456B1 (sr) * 2011-08-01 2019-04-30 Univ Monash Postupak i formulacije za inhalaciju
US10328061B2 (en) * 2016-05-02 2019-06-25 Florida State University Research Foundation, Inc. Treatment of Zika virus infections using alpha-glucosidase inhibitors
EP3934688A4 (en) * 2019-03-08 2022-12-21 University of Virginia Patent Foundation COMPOSITIONS AND METHODS FOR MODULATION OF VIRAL INFECTION THROUGH REGULATION OF GLUCOSYLCERAMIDS
EP4106752A4 (en) * 2020-02-21 2024-03-20 Florida State University Research Foundation, Inc. TREATMENT OF HUMAN CORONAVIRUS INFECTIONS USING ALPHA-GLUCOSIDASE-GLYCOPROTEIN PROCESSING INHIBITORS
US10980756B1 (en) * 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
CN113425720A (zh) * 2020-04-03 2021-09-24 深圳前海诺贝尔奖科学家技术转移转化有限公司 亚胺糖化合物在制备抗SARS-CoV-2病毒的药物中的用途
US20230270826A1 (en) * 2020-07-30 2023-08-31 Delta 4 Gmbh Antiviral use of liraglutide and gefitinib

Similar Documents

Publication Publication Date Title
US9278975B2 (en) Pyrazolo[1,5-A]pyrimidines as antiviral agents
KR102102283B1 (ko) 항바이러스 치료를 위한 화합물 및 방법
JP2024522494A5 (cg-RX-API-DMAC7.html)
JP2021534124A5 (cg-RX-API-DMAC7.html)
JP2022512482A5 (cg-RX-API-DMAC7.html)
JP2019501133A5 (cg-RX-API-DMAC7.html)
RU2015129062A (ru) Соединения 3, 5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида
JP2017019850A (ja) 抗ウイルス剤としてのピラゾロ[1,5−a]ピリミジン
TW201925196A (zh) 流感病毒複製之抑制劑
JP2018536681A (ja) インフルエンザウイルス複製の阻害剤、その適用方法および使用
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2019526596A5 (cg-RX-API-DMAC7.html)
JP2017531619A5 (cg-RX-API-DMAC7.html)
JP2020500866A5 (cg-RX-API-DMAC7.html)
JP2015521617A5 (cg-RX-API-DMAC7.html)
JP2020097577A5 (cg-RX-API-DMAC7.html)
JP5132554B2 (ja) Tpo模倣剤としてのヘテロ四環化合物
HK1214243A1 (zh) 制备喹诺酮类化合物的工艺
JP2011526286A5 (cg-RX-API-DMAC7.html)
TWI778052B (zh) 流感病毒複製之抑制劑
MX2024014315A (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
CN104981469B (zh) 抗微生物剂
RU2012155691A (ru) Производные сложного аминоэфира алкалоида и их лекарственные композиции
WO2022036774A1 (zh) 单宁酸在制备抗呼吸道病毒药物方面的应用
RU2012155716A (ru) Алкалоидные производные на основе сложных аминоэфиров и композиции лекарственных средств, содержащие их